The LANTERN trial, a phase II trial comparing lapatinib-capecitabine versus trastuzumab-capecitabine therapy in HER2 + BC with CNS metastasis showed no significant difference in PFS but a trend favoring trastuzumab-capecitabine [45]. Here, ERBB2 is linked to breast cancer.